FIP was historically a fatal disease in cats; antiviral treatments introduced since 2019 have transformed it from a death sentence to a treatable condition.
The transformation of FIP from inevitable death to treatable condition is one of the most significant welfare advances in companion animal medicine in recent years. Before effective antivirals, cats with FIP died within days to weeks of diagnosis despite supportive care. GS-441524 treatment produces remission in most treated cats who complete the full course, with most achieving long-term disease-free status. The challenge has been access: the drug was initially available only through gray-market sources in many countries due to regulatory delays. FIP advocacy communities formed globally to help owners access treatment and navigate the complex regulatory landscape. Veterinary prescribing of licensed antivirals is expanding as regulatory approvals proceed, improving both access and treatment oversight.